Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism.
OBJECTIVE Increased serum ferritin levels and iron stores may be involved in the development of abnormal glucose tolerance in women presenting with obesity and/or polycystic ovary syndrome (PCOS). We aimed to study the determinants of serum ferritin levels in premenopausal women among indexes of insulin resistance, adiposity, hyperandrogenism, and genotypes pertaining to inflammation, oxidative stress, and iron metabolism. RESEARCH DESIGN AND METHODS A total of 257 premenopausal women, classified depending on the presence or absence of PCOS, obesity, and/or abnormal glucose tolerance, underwent a complete metabolic evaluation, serum ferritin, haptoglobin, and C-reactive protein (CRP) measurements, and genotyping for proinflammatory and prooxidant variants and mutations in the HFE gene. RESULTS Serum ferritin concentrations were increased in women presenting with PCOS and/or abnormal glucose tolerance, independent of obesity. A stepwise multivariate linear regression analysis (R(2) = 0.18, P < 0.0001) retained menstrual dysfunction (beta = 0.14, P = 0.035), free testosterone (beta = 0.14, P = 0.052), insulin sensitivity index (beta = -0.12, P = 0.012), the His63Asp variant in HFE (beta = 0.16, P = 0.008), and abnormal glucose tolerance (beta = 0.15, P = 0.015) as significant predictors of the logarithm of ferritin levels, whereas CRP, haptoglobin, waist-to-hip ratio, or variants in the TNFalpha, TNFRSF1B, IL6, IL6ST, IL6Ralpha, PON1, and HFE Cys282Tyr mutation exerted no influence. CONCLUSIONS Androgen excess (partly because of hyperandrogenemia and partly because of menstrual dysfunction), insulin resistance, abnormal glucose tolerance, and the HFE His63Asp variant correlate with ferritin levels in premenopausal women.
Martínez-García
M Angeles
MA
Department of Endocrinology, Hospital Universitario Ramón y Cajal and Universidad de Alcala, Madrid, Spain.
Luque-Ramírez
Manuel
M
San-Millán
José L
JL
Escobar-Morreale
Héctor F
HF
D000328:Adult; D043303:Aryldialkylphosphatase / Q000235:genetics; D015992:Body Mass Index; D004247:DNA / Q000097:blood / Q000235:genetics; D005091:Exons; D005260:Female; D005293:Ferritins / Q000097:blood; D014644:Genetic Variation; D018149:Glucose Intolerance / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000235:genetics* / Q000503:physiopathology; D007333:Insulin Resistance / Q000502:physiology*; D015850:Interleukin-6 / Q000235:genetics; D007501:Iron / Q000378:metabolism*; D008597:Menstrual Cycle / Q000502:physiology; D009765:Obesity / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D018384:Oxidative Stress / Q000235:genetics; D011085:Polycystic Ovary Syndrome / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D011110:Polymorphism, Genetic; D017697:Premenopause / Q000502:physiology*; D012016:Reference Values; D050800:STAT6 Transcription Factor / Q000235:genetics
D015850:Interleukin-6; D050800:STAT6 Transcription Factor; D004247:DNA; D005293:Ferritins; D007501:Iron; D043303:Aryldialkylphosphatase